Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in relapsing multiple sclerosis in China
NCT04667949Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Adjusted Annualized Relapse Rate at 24 months. Started Feb 2021; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04667949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667949.